Cargando…
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
OBJECTIVES: Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the preferential Janus kinase 1 (JAK1) inhibitor filgoti...
Autores principales: | Baker, Matthew, Chaichian, Yashaar, Genovese, Mark, Derebail, Vimal, Rao, Panduranga, Chatham, Winn, Bubb, Michael, Lim, Sam, Hajian, Hooman, Gurtovaya, Oksana, Patel, Uptal, Tumlin, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780527/ https://www.ncbi.nlm.nih.gov/pubmed/33380521 http://dx.doi.org/10.1136/rmdopen-2020-001490 |
Ejemplares similares
-
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021) -
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
por: Price, Elizabeth, et al.
Publicado: (2022) -
Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019) -
The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus
por: Falasinnu, Titilola, et al.
Publicado: (2018) -
Escaping the catch 22 of lupus anticoagulant testing
por: Vinholt, Pernille Just, et al.
Publicado: (2020)